NCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07516093 2026-04-08
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT07101328 2026-03-20
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT07439653 2026-02-27
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2 Not yet recruiting
NCT06970496 2025-11-20
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT06894693 2025-03-25
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT06314828 2024-03-18
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT06142188 2023-11-21
Relmacabtagene Autoleucel in Hematologic Malignancies
Shanghai Ming Ju Biotechnology Co., Ltd.
Not yet recruiting
NCT05091541 2021-10-25
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting